ArticlePloS one2021

EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.

Joyce H S You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.